Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.81 - $50.89
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.09M
Market Cap
$5.08B
Enterprise Value$4.28B
Total Cash (Recent Filing)-$95.26M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Apr 30, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding123,421,440
10 Day Avg. Volume1,921,643
30 Day Avg. Volume2,085,416
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.70
Price to Cash Flow (P/CF)-22.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.52
Enterprise Value/Ebitda-10.96
Forecast
1Y Price Target
$56.47Price Target Upside29.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Insurance CoverageGH announced that Shield had received coverage by a key healthcare insurance program for U.S. veterans.
Market OpportunityThere is a near-term access to almost $20 billion of Precision Oncology total addressable market between Colorectal, Breast, and Lung indications.
Reimbursement IncreaseGH obtained ADLT status for its blood-based Shield CRC test, which increases the company's Medicare rate for Shield from $920 to $1,495 per test, marking a significant milestone in the diagnostics industry.
Bears Say
CompetitionSmart Liquid Biopsy is highlighted as a differentiated platform versus tissue-based competition.
Reimbursement StrategyThe strategy is likely to focus on only signing private-payer contracts that are at or near the list price, resulting in little degradation from the list price.
---
Ownership Overview
4.01% Insiders
31.59% Mutual Funds
36.59% Other Institutional Investors
10.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $50.89 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $5.08B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Apr 30, 2025 which is in 16 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Feb 20, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.765 by -$0.135.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.75.
How many shares outstanding does Guardant Health have?
Guardant Health has 123,421,440 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.765. Following the earnings report the stock price went down -9.557%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
---
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.47 (29.19% Upside)
$56.47 (29.19% Upside)
Blogger Sentiment
Bullish
GH Sentiment 85%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 112.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $164.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.99%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-16.84%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
---
GH Company Deck
---
GH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, significant product upgrades, and successful cost reductions, indicating a positive trajectory for Guardant Health. However, litigation expenses and challenges with NCCN guidelines presented some obstacles. Overall, the positive developments outweighed the lowlights.Read More>---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$56.47
▲(29.19% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+40.19%
reiterated a buy rating 2 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +40.19% per trade.
---